Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526212 | 0.83 | MMP9 (0.30) | MMP9 | |
| SCHEMBL2367994 | 0.80 | — | — | |
| SCHEMBL510489 | 0.79 | MEN1 (0.31) | — | |
| SCHEMBL27685291 | 0.71 | MMP9 (0.31) | MMP9 | |
| SCHEMBL1618688 | 0.70 | — | — | |
| SCHEMBL2367586 | 0.64 | — | — | |
| SCHEMBL632195 | 0.64 | — | — | |
| SCHEMBL2368023 | 0.64 | SORT1 (0.33) | FAAH | |
| SCHEMBL868123 | 0.61 | — | — | |
| SCHEMBL24376349 | 0.60 | PTPN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | ALCON INC. (CH) | 2026-05-26 | — | — | US | claimed |
| US-20260131506-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-05-14 | — | — | US | claimed |
| US-12595368-B2 | UV/HEVL-filtering contact lenses | ALCON INC. (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4713721-A1 | UV/HEVL-FILTERING SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | claimed |
| US-12570784-B2 | Method for making embedded hydrogel contact lenses | ALCON INC. (CH) | 2026-03-10 | — | — | US | claimed |
| EP-4514596-B1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-03-04 | — | — | EP | claimed |
| EP-3759528-B1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-03-04 | — | — | EP | claimed |
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | ALCON INC. (CH) | 2026-02-03 | — | — | US | claimed |
| US-20250347826-A1 | METHOD FOR PRODUCING WETTABLE SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2025-11-13 | — | — | US | claimed |
| US-20250340028-A1 | CONTACT LENSES WITH SOFTER LENS SURFACES | ALCON INC (CH) | 2025-11-06 | — | — | US | claimed |
| US-20030162862-A1 | Contact lenses for extended wear (without surface treatment, coating-free), formed by reacting polyvinylpyrrolidone and (2-methacryloxy-3-hydroxypropyloxy)propylbis(trimethylsiloxy) methylsilane, then curing | JOHNSON & JOHNSON VISION CARE, INC. | 2003-08-28 | — | — | US | claimed |
| US-20030125498-A1 | Biomedical devices containing internal wetting agents | JOHNSON & JOHNSON VISION CARE, INC. | 2003-07-03 | — | — | US | claimed |
| WO-2003022322-A2 | BIOMEDICAL DEVICES CONTAINING INTERNAL WETTING AGENTS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2003022321-A2 | BIOMEDICAL DEVICES CONTAINING INTERNAL WETTING AGENTS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| CN-1283280-A | Actively controllable multifocal lens | NOVARTIS AG (CH) | 2001-02-07 | — | — | CN | claimed |
| EP-1044389-A2 | ACTIVELY CONTROLLABLE MULTIFOCAL LENS | Novartis AG (CH) | 2000-10-18 | — | — | EP | claimed |
| US-5997140-A | Actively controllable multifocal lens | NOVARTIS AG (CH) | 1999-12-07 | — | — | US | claimed |
| WO-1999034239-A2 | ACTIVELY CONTROLLABLE MULTIFOCAL LENS | NOVARTIS AG (CH) | 1999-07-08 | — | — | WO | claimed |
| US-4123408-A | Hydrogel contact lens | AMERICAN OPTICAL CORPORATION (US) | 1978-10-31 | — | — | US | claimed |
| US-4123407-A | Hydrophilic contact lens | AMERICAN OPTICAL CORPORATION (US) | 1978-10-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | INF2, CRYZ, CRYAA | MMP9 3923/4885FAAH 3238/4885 |
| US-12595368-B2 | UV/HEVL-filtering contact lenses | UACA, HSPA4L, RAD54L | MMP9 4616/4885FAAH 3553/4885 |
| US-12570784-B2 | Method for making embedded hydrogel contact lenses | CRYAB, CRYZ, CRYAA | MMP9 4041/4885FAAH 4264/4885 |
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | SMCHD1, CRYAA, CRYZ | MMP9 1813/4885FAAH 913/4885 |
| US-20260131506-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | CRYZ, CRYAB, CRYAA | MMP9 4245/4885FAAH 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.